article thumbnail

After IPO fails, imaging agent developer Telix Pharmaceuticals raises $429M via debt

Radiology Business

The Melbourne, Australia-based radiopharmaceutical firm plans to use the proceeds to accelerate development of products in its theranostics portfolio

article thumbnail

Telix partners with Subtle Medical on PSMA-PET software

AuntMinnie

Telix Pharmaceuticals has entered an agreement to add Subtle Medical’s AI software for enhancing prostate-specific membrane antigen (PSMA) PET prostate cancer scans to its product portfolio. SubtlePET is a U.S.

PET Scan 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA denies pharma firm’s initial application for new kidney cancer imaging agent

Radiology Business

Telix Pharmaceuticals Ltd. announced the news on July 31, with the decision applying to its TLX250-CDx investigational agent for clear cell renal cell carcinoma (brand name Zircaix).

article thumbnail

Eckert & Ziegler and Actinium ink Ac-225 agreement

AuntMinnie

Eckert & Ziegler has entered into an agreement with Actinium Pharmaceuticals to supply the firm with the radioisotope actinium-225 (Ac-225). Actinium will continue developing its lead radiopharmaceutical product Actimab-A, as well as additional early and late-stage development candidates for both U.S. and international clinical trials.

article thumbnail

Pharmacy firm eyes 2024 rollout of 1st targeted PET imaging agent for kidney cancer

Radiology Business

Telix Pharmaceuticals recently submitted its license application to the FDA for the investigational positron emission tomography agent TLX250-CDx (Zircaix).

article thumbnail

Lawsuit accuses radiology AI vendor MIM Software of patent theft

Radiology Business

Progenics Pharmaceuticals Inc. claims MIM stole its patents and used them to help entice GE HealthCare to buy the company in January.

article thumbnail

Telix to purchase ImaginAb assets

AuntMinnie

Telix Pharmaceuticals has entered into an asset purchase agreement with ImaginAb initially worth $45 million. Under terms of the deal, Telix will acquire a pipeline of therapeutic candidates such as DLL3 and integrin v6, a biologics technology platform, and a protein engineering and discovery research facility in California, it said.